White Matter Changes in Cervical Dystonia Relate to Clinical Effectiveness of Botulinum Toxin Treatment

In a previous report showing white matter microstructural hemispheric asymmetries medial to the pallidum in focal dystonias, we showed preliminary evidence that this abnormality was reduced 4 weeks after botulinum toxin (BTX) injections. In the current study we report the completed treatment study i...

Full description

Bibliographic Details
Main Authors: Anne J. Blood, John K. Kuster, Jeff L. Waugh, Jacob M. Levenstein, Trisha J. Multhaupt-Buell, Lewis R. Sudarsky, Hans C. Breiter, Nutan Sharma
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-04-01
Series:Frontiers in Neurology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fneur.2019.00265/full
id doaj-e01c2f4025cc42c6b60f44cfb70e9866
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Anne J. Blood
Anne J. Blood
Anne J. Blood
Anne J. Blood
Anne J. Blood
Anne J. Blood
John K. Kuster
John K. Kuster
John K. Kuster
John K. Kuster
John K. Kuster
Jeff L. Waugh
Jeff L. Waugh
Jeff L. Waugh
Jeff L. Waugh
Jeff L. Waugh
Jacob M. Levenstein
Jacob M. Levenstein
Jacob M. Levenstein
Trisha J. Multhaupt-Buell
Lewis R. Sudarsky
Lewis R. Sudarsky
Hans C. Breiter
Hans C. Breiter
Hans C. Breiter
Hans C. Breiter
Hans C. Breiter
Hans C. Breiter
Hans C. Breiter
Nutan Sharma
Nutan Sharma
Nutan Sharma
spellingShingle Anne J. Blood
Anne J. Blood
Anne J. Blood
Anne J. Blood
Anne J. Blood
Anne J. Blood
John K. Kuster
John K. Kuster
John K. Kuster
John K. Kuster
John K. Kuster
Jeff L. Waugh
Jeff L. Waugh
Jeff L. Waugh
Jeff L. Waugh
Jeff L. Waugh
Jacob M. Levenstein
Jacob M. Levenstein
Jacob M. Levenstein
Trisha J. Multhaupt-Buell
Lewis R. Sudarsky
Lewis R. Sudarsky
Hans C. Breiter
Hans C. Breiter
Hans C. Breiter
Hans C. Breiter
Hans C. Breiter
Hans C. Breiter
Hans C. Breiter
Nutan Sharma
Nutan Sharma
Nutan Sharma
White Matter Changes in Cervical Dystonia Relate to Clinical Effectiveness of Botulinum Toxin Treatment
Frontiers in Neurology
botulinum toxin
basal ganglia
dystonia
ansa lenticularis
white matter plasticity
diffusion tensor imaging
author_facet Anne J. Blood
Anne J. Blood
Anne J. Blood
Anne J. Blood
Anne J. Blood
Anne J. Blood
John K. Kuster
John K. Kuster
John K. Kuster
John K. Kuster
John K. Kuster
Jeff L. Waugh
Jeff L. Waugh
Jeff L. Waugh
Jeff L. Waugh
Jeff L. Waugh
Jacob M. Levenstein
Jacob M. Levenstein
Jacob M. Levenstein
Trisha J. Multhaupt-Buell
Lewis R. Sudarsky
Lewis R. Sudarsky
Hans C. Breiter
Hans C. Breiter
Hans C. Breiter
Hans C. Breiter
Hans C. Breiter
Hans C. Breiter
Hans C. Breiter
Nutan Sharma
Nutan Sharma
Nutan Sharma
author_sort Anne J. Blood
title White Matter Changes in Cervical Dystonia Relate to Clinical Effectiveness of Botulinum Toxin Treatment
title_short White Matter Changes in Cervical Dystonia Relate to Clinical Effectiveness of Botulinum Toxin Treatment
title_full White Matter Changes in Cervical Dystonia Relate to Clinical Effectiveness of Botulinum Toxin Treatment
title_fullStr White Matter Changes in Cervical Dystonia Relate to Clinical Effectiveness of Botulinum Toxin Treatment
title_full_unstemmed White Matter Changes in Cervical Dystonia Relate to Clinical Effectiveness of Botulinum Toxin Treatment
title_sort white matter changes in cervical dystonia relate to clinical effectiveness of botulinum toxin treatment
publisher Frontiers Media S.A.
series Frontiers in Neurology
issn 1664-2295
publishDate 2019-04-01
description In a previous report showing white matter microstructural hemispheric asymmetries medial to the pallidum in focal dystonias, we showed preliminary evidence that this abnormality was reduced 4 weeks after botulinum toxin (BTX) injections. In the current study we report the completed treatment study in a full-size cohort of CD patients (n = 14). In addition to showing a shift toward normalization of the hemispheric asymmetry, we evaluated clinical relevance of these findings by relating white matter changes to degree of symptom improvement. We also evaluated whether the magnitude of the white matter asymmetry before treatment was related to severity, laterality, duration of dystonia, and/or number of previous BTX injections. Our results confirm the findings of our preliminary report: we observed significant fractional anisotropy (FA) changes medial to the pallidum 4 weeks after BTX in CD participants that were not observed in controls scanned at the same interval. There was a significant relationship between magnitude of hemispheric asymmetry and dystonia symptom improvement, as measured by percent reduction in dystonia scale scores. There was also a trend toward a relationship between magnitude of pre-injection white matter asymmetry and symptom severity, but not symptom laterality, disorder duration, or number of previous BTX injections. Post-hoc analyses suggested the FA changes at least partially reflected changes in pathophysiology, but a dissociation between patient perception of benefit from injections and FA changes suggested the changes did not reflect changes to the primary “driver” of the dystonia. In contrast, there were no changes or group differences in DTI diffusivity measures, suggesting the hemispheric asymmetry in CD does not reflect irreversible white matter tissue loss. These findings support the hypothesis that central nervous system white matter changes are involved in the mechanism by which BTX exerts clinical benefit.
topic botulinum toxin
basal ganglia
dystonia
ansa lenticularis
white matter plasticity
diffusion tensor imaging
url https://www.frontiersin.org/article/10.3389/fneur.2019.00265/full
work_keys_str_mv AT annejblood whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT annejblood whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT annejblood whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT annejblood whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT annejblood whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT annejblood whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT johnkkuster whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT johnkkuster whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT johnkkuster whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT johnkkuster whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT johnkkuster whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT jefflwaugh whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT jefflwaugh whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT jefflwaugh whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT jefflwaugh whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT jefflwaugh whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT jacobmlevenstein whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT jacobmlevenstein whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT jacobmlevenstein whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT trishajmulthauptbuell whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT lewisrsudarsky whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT lewisrsudarsky whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT hanscbreiter whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT hanscbreiter whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT hanscbreiter whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT hanscbreiter whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT hanscbreiter whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT hanscbreiter whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT hanscbreiter whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT nutansharma whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT nutansharma whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
AT nutansharma whitematterchangesincervicaldystoniarelatetoclinicaleffectivenessofbotulinumtoxintreatment
_version_ 1725323874474655744
spelling doaj-e01c2f4025cc42c6b60f44cfb70e98662020-11-25T00:31:05ZengFrontiers Media S.A.Frontiers in Neurology1664-22952019-04-011010.3389/fneur.2019.00265432363White Matter Changes in Cervical Dystonia Relate to Clinical Effectiveness of Botulinum Toxin TreatmentAnne J. Blood0Anne J. Blood1Anne J. Blood2Anne J. Blood3Anne J. Blood4Anne J. Blood5John K. Kuster6John K. Kuster7John K. Kuster8John K. Kuster9John K. Kuster10Jeff L. Waugh11Jeff L. Waugh12Jeff L. Waugh13Jeff L. Waugh14Jeff L. Waugh15Jacob M. Levenstein16Jacob M. Levenstein17Jacob M. Levenstein18Trisha J. Multhaupt-Buell19Lewis R. Sudarsky20Lewis R. Sudarsky21Hans C. Breiter22Hans C. Breiter23Hans C. Breiter24Hans C. Breiter25Hans C. Breiter26Hans C. Breiter27Hans C. Breiter28Nutan Sharma29Nutan Sharma30Nutan Sharma31Mood and Motor Control Laboratory, Massachusetts General Hospital (MGH), Charlestown, MA, United StatesLaboratory of Neuroimaging and Genetics, Massachusetts General Hospital, Charlestown, MA, United StatesDepartment of Neurology, Massachusetts General Hospital, Boston, MA, United StatesDepartment of Psychiatry, Massachusetts General Hospital, Boston, MA, United StatesMartinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, United StatesDepartment of Psychiatry, Harvard Medical School, Boston, MA, United StatesMood and Motor Control Laboratory, Massachusetts General Hospital (MGH), Charlestown, MA, United StatesLaboratory of Neuroimaging and Genetics, Massachusetts General Hospital, Charlestown, MA, United StatesDepartment of Neurology, Massachusetts General Hospital, Boston, MA, United StatesDepartment of Psychiatry, Massachusetts General Hospital, Boston, MA, United StatesMartinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, United StatesMood and Motor Control Laboratory, Massachusetts General Hospital (MGH), Charlestown, MA, United StatesDepartment of Neurology, Massachusetts General Hospital, Boston, MA, United StatesMartinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, United StatesDivision of Child Neurology, Boston Children's Hospital, Boston, MA, United StatesDepartment of Neurology, Harvard Medical School, Boston, MA, United StatesMood and Motor Control Laboratory, Massachusetts General Hospital (MGH), Charlestown, MA, United StatesDepartment of Psychiatry, Massachusetts General Hospital, Boston, MA, United StatesMartinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, United StatesDepartment of Neurology, Massachusetts General Hospital, Boston, MA, United StatesDepartment of Neurology, Harvard Medical School, Boston, MA, United StatesDepartment Neurology, Brigham and Women's Hospital, Boston, MA, United StatesMood and Motor Control Laboratory, Massachusetts General Hospital (MGH), Charlestown, MA, United StatesLaboratory of Neuroimaging and Genetics, Massachusetts General Hospital, Charlestown, MA, United StatesDepartment of Psychiatry, Massachusetts General Hospital, Boston, MA, United StatesMartinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, United StatesDepartment of Psychiatry, Harvard Medical School, Boston, MA, United States0Department of Radiology, Massachusetts General Hospital, Boston, MA, United States1Warren Wright Adolescent Center, Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, United StatesDepartment of Neurology, Massachusetts General Hospital, Boston, MA, United StatesDepartment of Neurology, Harvard Medical School, Boston, MA, United StatesDepartment Neurology, Brigham and Women's Hospital, Boston, MA, United StatesIn a previous report showing white matter microstructural hemispheric asymmetries medial to the pallidum in focal dystonias, we showed preliminary evidence that this abnormality was reduced 4 weeks after botulinum toxin (BTX) injections. In the current study we report the completed treatment study in a full-size cohort of CD patients (n = 14). In addition to showing a shift toward normalization of the hemispheric asymmetry, we evaluated clinical relevance of these findings by relating white matter changes to degree of symptom improvement. We also evaluated whether the magnitude of the white matter asymmetry before treatment was related to severity, laterality, duration of dystonia, and/or number of previous BTX injections. Our results confirm the findings of our preliminary report: we observed significant fractional anisotropy (FA) changes medial to the pallidum 4 weeks after BTX in CD participants that were not observed in controls scanned at the same interval. There was a significant relationship between magnitude of hemispheric asymmetry and dystonia symptom improvement, as measured by percent reduction in dystonia scale scores. There was also a trend toward a relationship between magnitude of pre-injection white matter asymmetry and symptom severity, but not symptom laterality, disorder duration, or number of previous BTX injections. Post-hoc analyses suggested the FA changes at least partially reflected changes in pathophysiology, but a dissociation between patient perception of benefit from injections and FA changes suggested the changes did not reflect changes to the primary “driver” of the dystonia. In contrast, there were no changes or group differences in DTI diffusivity measures, suggesting the hemispheric asymmetry in CD does not reflect irreversible white matter tissue loss. These findings support the hypothesis that central nervous system white matter changes are involved in the mechanism by which BTX exerts clinical benefit.https://www.frontiersin.org/article/10.3389/fneur.2019.00265/fullbotulinum toxinbasal gangliadystoniaansa lenticulariswhite matter plasticitydiffusion tensor imaging